Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • OxyContin maker Purdue...

    OxyContin maker Purdue Pharma agrees to settle Oklahoma opioid case: Source

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-26T09:25:27+05:30  |  Updated On 16 Aug 2021 1:51 PM IST

    U.S: Purdue Pharma LP has agreed to settle a lawsuit by the state of Oklahoma accusing the OxyContin painkiller maker of helping fuel an opioid abuse epidemic, a person familiar with the matter said.


    It is the first settlement to result from a wave of recent lawsuits over the drugmaker's marketing of painkillers.


    Read Also: Purdue Pharma considers bankruptcy over OxyContin trial


    The settlement with Oklahoma Attorney General Mike Hunter came just weeks before Purdue, owned by members of the wealthy Sackler family, was set to face the first trial to result from around 2,000 lawsuits nationally against opioid manufacturers.


    Hunter's 2017 lawsuit accuses Purdue, Johnson & Johnson & Teva Pharmaceutical Industries Ltd of engaging in deceptive marketing that downplayed the risks of addiction associated with opioid pain drugs while overstating their benefits.


    The companies deny wrongdoing. They had sought to delay the May 28 trial to Sept. 16, citing the need to review records the state belatedly turned over that could be critical to their defense. The state had been seeking over $20 billion in damages.


    Read Also: OxyContin maker Purdue Pharma accused of deceiving patients and doctors


    But a trial judge earlier this month rejected the companies' efforts to delay the trial, and on Monday, Oklahoma's Supreme Court rejected their appeal of that decision.


    Stamford, Connecticut-based Purdue had been exploring filing for Chapter 11 bankruptcy protection to address potential liabilities stemming from the lawsuits, people familiar with the matter have told Reuters.


    Hunter is scheduled to hold a press conference on Tuesday to announce a "breaking development" in the lawsuit. A spokesman for Hunter declined to comment. A lawyer for Purdue did not respond to a request for comment.


    Opioids, including prescription painkillers, heroin and fentanyl, were involved in a record 47,600 overdose deaths in 2017 in the United States, according to the U.S. Centers for Disease Control and Prevention.


    Read Also: OxyContin maker Purdue taps financial restructuring adviser – sources


    The epidemic has prompted lawsuits by state and local governments accusing various drugmakers of contributing to the crisis. Those companies include Purdue, which introduced the painkiller OxyContin to the market in 1996.


    More than 1,600 lawsuits have been consolidated before a federal judge in Ohio, who has pushed for a settlement ahead of the trial before him in October. Other cases, including Oklahoma's, are pending in state courts.


    Purdue has held discussions to resolve the litigation with plaintiffs' lawyers, who have often compared the cases to widespread lawsuits against the tobacco industry that resulted in a $246 billion settlement in 1998.

    bankruptcyfederal judge ohiofentanylheroinJnJJohnson & JohnsonMike HunterohioOklahoma Attorney GeneralOklahoma opioid caseopioidOxyContinOxyContin painkillerpainkillersPurduePurdue PharmaPurdue Pharma LPStamfordSupreme CourtTeva PharmaceuticalUnited States
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok